Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

ADVERTISEMENT

Early and Metastatic Breast Cancer Excellence Forum

Early and Metastatic Breast Cancer
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Reshma Mahtani, DO, Terry Mamounas, MD, Jane Meisel, MD
Videos
Neoadjuvant vs Adjuvant Therapy for Early-Stage HER2-Positive Breast Cancer
02/15/2024
In this video, a panel of experts discuss approaches to neoadjuvant and adjuvant therapy for early-stage HER2-positive breast cancer and the value of achieving a pathological complete response from the surgical and medical oncology...
In this video, a panel of experts discuss approaches to neoadjuvant and adjuvant therapy for early-stage HER2-positive breast cancer and the value of achieving a pathological complete response from the surgical and medical oncology...
In this video, a panel of...
02/15/2024
Oncology
John A. Ingoglia, PharmD
Videos
Utilizing Clinical Pathways Tools at Cone Health
10/31/2023

Featuring John A. Ingoglia, PharmD, BCOP, CPP

Featuring John A. Ingoglia, PharmD, B...
John A. Ingoglia, PharmD, BCOP, CPP, Cone Health, provides an overview of how clinical pathways are utilized at Cone Health and shares some of the latest treatment options for breast cancer.
John A. Ingoglia, PharmD, BCOP, CPP, Cone Health, provides an overview of how clinical pathways are utilized at Cone Health and shares some of the latest treatment options for breast cancer.
John A. Ingoglia, PharmD, BCOP,...
10/31/2023
Journal of Clinical Pathways
News
How Clinical Pathways Can be Used For HER2-Positive Breast Cancer Therapies
10/07/2023

Emry Lloyd

Emry Lloyd
At CPC & CBEx 2023, Sayeh Lavasani, MD, discussed the different ways clinical pathways can be followed for HER2-positive breast cancer therapies.
At CPC & CBEx 2023, Sayeh Lavasani, MD, discussed the different ways clinical pathways can be followed for HER2-positive breast cancer therapies.
At CPC & CBEx 2023, Sayeh...
10/07/2023
Journal of Clinical Pathways
Scott Swain, PhD.
Videos
Comparing Diversity in Real-World Evidence With Diversity in Clinical Trial and SEER Data
08/10/2023
Scott Swain, PhD, discusses his study on comparison of diversity across real-world evidence with clinical trial and SEER data in patients with metastatic breast cancer.
Scott Swain, PhD, discusses his study on comparison of diversity across real-world evidence with clinical trial and SEER data in patients with metastatic breast cancer.
Scott Swain, PhD, discusses his...
08/10/2023
Journal of Clinical Pathways
Dr Danielle Gentile.
Videos
Comparison of Diversity Across Real-World Evidence, Randomized Clinical Trial, and SEER Data in Patients With Metastatic Breast Cancer
07/12/2023

Featuring Danielle Gentile, PhD

Featuring Danielle Gentile, PhD ...
Danielle Gentile, PhD, a senior scientist on Cardinal Health’s real-world evidence and insights team, discusses her research comparing diversity in real-world evidence, RCTs, and SEER data in patients with metastatic breast cancer.
Danielle Gentile, PhD, a senior scientist on Cardinal Health’s real-world evidence and insights team, discusses her research comparing diversity in real-world evidence, RCTs, and SEER data in patients with metastatic breast cancer.
Danielle Gentile, PhD, a senior...
07/12/2023
Journal of Clinical Pathways
Dr Barb Kunz.
Videos
The Impact of Social Determinants of Health on Use of Germline Genetic Testing for Triple-Negative Breast Cancer
06/20/2023

Featuring Barb Kunz

Featuring Barb Kunz
Barb Kunz, the US Oncology Network, discusses her study on the impact of social determinants of health on use of germline genetic testing for triple-negative breast cancer in the community oncology setting.
Barb Kunz, the US Oncology Network, discusses her study on the impact of social determinants of health on use of germline genetic testing for triple-negative breast cancer in the community oncology setting.
Barb Kunz, the US Oncology...
06/20/2023
Journal of Clinical Pathways
Dr Andrew Hertler.
Videos
Accelerating Adoption of Hypofractionation in Patients with Early-Stage Breast Cancer
05/19/2023

Featuring Andrew Hertler, MD 

Featuring Andrew Hertler, MD 
Andrew Hertler, MD, Chief Medical Officer, New Century Health, discusses his study on the use of hypofractionation in patients with early-stage breast cancer.
Andrew Hertler, MD, Chief Medical Officer, New Century Health, discusses his study on the use of hypofractionation in patients with early-stage breast cancer.
Andrew Hertler, MD, Chief...
05/19/2023
Journal of Clinical Pathways
Jason Mouabbi, MD
Videos
The Impact of HER2-low Status on Prognosis in Hormone Receptor-Positive Metastatic Breast Cancer Treated With a Targeted Therapy Plus Endocrine Therapy
12/08/2022
Jason Mouabbi, MD, discusses his presentation from the 2022 San Antonio Breast Cancer Symposium on survival outcomes among patients with hormone receptor-positive, HER2-negative metastatic breast cancer, finding that HER2-low status may not...
Jason Mouabbi, MD, discusses his presentation from the 2022 San Antonio Breast Cancer Symposium on survival outcomes among patients with hormone receptor-positive, HER2-negative metastatic breast cancer, finding that HER2-low status may not...
Jason Mouabbi, MD, discusses his...
12/08/2022
Journal of Clinical Pathways
Sayeh Lavasani, MD, MS, FRCPC
Videos
Utilizing Pathways to Mitigate Costs in Metastatic Breast Cancer Treatment
10/16/2022
Sayeh Lavasani, MD, MS, FRCPC, highlights the financial advantage of pathways, stating that clinical pathway utilization can save up to 35% in the cost of treatment in breast cancer, while providing up-to-date, evidence-based treatment...
Sayeh Lavasani, MD, MS, FRCPC, highlights the financial advantage of pathways, stating that clinical pathway utilization can save up to 35% in the cost of treatment in breast cancer, while providing up-to-date, evidence-based treatment...
Sayeh Lavasani, MD, MS, FRCPC,...
10/16/2022
Journal of Clinical Pathways
Sara Tolaney, MD, MPH
Videos
Factors Associated With a Greater Risk of Treatment Discontinuation in High-Risk Early Breast Cancer
08/03/2022
Sara Tolaney, MD, MPH, discusses results from the adjuvant abemaciclib trial monarche, analyzing factors that were associated with an increased risk of treatment discontinuation among patients who had high risk hormone receptor positive,...
Sara Tolaney, MD, MPH, discusses results from the adjuvant abemaciclib trial monarche, analyzing factors that were associated with an increased risk of treatment discontinuation among patients who had high risk hormone receptor positive,...
Sara Tolaney, MD, MPH, discusses...
08/03/2022
Journal of Clinical Pathways

Advertisement

Advertisement

JCP March/April 2024

Current Issue

April 2024
Volume 10
Issue 2
Current Issue
Issue Archive

Advertisement

Advertisement

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Winston Wong, PharmD
Gordon Kuntz
Robin T Zon, MD, FACP, FASCO
2021 Care Pathways Working Group
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Advertisement

Subscribe

Journal of Clinical Pathways Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement